Drugs / IBI351
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05699993 | Mar → Oct 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05626179 | Feb → Mar 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05688124 | Feb → Oct 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05504278 | Sep 2022 → May 2025 overdue | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05497336 | Aug 2022 → Aug 2023 | colorectal cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05756153 | Apr 2023 → Apr 2025 | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05005234 | Sep 2021 → Feb 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07198841 | Nov 2025 → Sep 2027 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
| Phase 2 | NCT06959589 | May 2025 → May 2027 expected | metastatic malignant neoplasm in the colon | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05504278 ↗ |
| Known as | GFH925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005234 ↗ |
| Action | Inhibit | “inhibitor of KRAS G12C” NCT05504278 ↗ |
| Modality | Small molecule | “orally available small molecule inhibitor” NCT05504278 ↗ |
| Route | Oral | “IBI351 is administered orally” NCT05497336 ↗ |
| Target | KRAS | “inhibitor of KRAS G12C” NCT05504278 ↗ |